AzTrials
AzTrials

DementiaLUMENNCT07347431

Large Language Model for Understanding and Monitoring Elderly Neurocognition

An observational study of Dementia, run by Northumbria Healthcare NHS Foundation Trust at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Dementia
What is being tested?
LUMEN prototype software interaction
Type of treatment
Pill or oral medicine
How many people
60 participants
Where
1 siteUnited Kingdom
Study dates
19 Mar 2026to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Patient and carer dyads: patients attending the Memory Clinic for assessment of cognitive problems. Clinicians: specialist doctors or advanced nurse practitioners responsible for dementia diagnosis

Carers of patients attending Memory Clinic appointments; Aged 18 or over; Both patients and cares can provide informed consent; Basic English literacy

Clinicians must have at least 2 years of specialist dementia care experience and be personally responsible for dementia diagnosis; Must be provide informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site, 1 recruiting
  • North Tyneside General Hospital is Rake Lane

    North Shields, NE29 8NH

    Lorelle Dismore, +44191 293 4087, lorelle.dismore@northumbria-healthcare.nhs.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition): A Clinical Feasibility Study With Nested Qualitative Evaluation for AI- Assisted Dementia Assessment

Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging.

This study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families.

Read more

We will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds.

This research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.

Read the detailed description
  1. Background and Rationale Dementia diagnosis relies on clinical history, cognitive assessments, and collateral information from caregivers. However, obtaining structured and reliable collateral histories is challenging due to caregiver burden, recall bias, and time constraints in memory clinics. Large language models (LLMs) have the potential to improve this process by guiding structured history-taking, extracting clinically relevant details, and standardising information gathering. LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition) is an AI-powered conversational tool designed to assist caregivers in providing structured collateral histories before clinical dementia assessments. Seed-funded by the Royal College of Psychiatrists, the Alzheimer's Research UK Northern Network and the Newcastle Biomedical Research Network, LUMEN was developed to enhance diagnostic accuracy, reduce caregiver burden, and improve workflow efficiency in memory clinics. This study will evaluate the feasibility, usability, and acceptability of LUMEN in real-world clinical settings through a nested qualitative feasibility study. We will recruit caregivers and clinicians to interact with LUMEN and assess its effectiveness in gathering collateral histories. The study will also incorporate co-production workshops with community groups to explore issues around language, cultural inclusivity, and accessibility. Findings will inform future refinements and a larger validation study.
  2. Research Objectives

This study aims to:

  1. Evaluate LUMEN's usability -Measure caregiver and clinician experiences using validated scales (System Usability Scale [SUS] and NASA Task Load Index [NASA-TLX]).
  2. Explore acceptability and implementation barriers and facilitators-Conduct qualitative interviews and coproduction workshops to refine LUMEN's design, ensuring accessibility across diverse user groups.
  3. Compare LUMEN's outputs to clinician assessments-Investigate the alignment between LUMEN-generated reports and clinician-elicited histories using Cohen's Kappa for inter-rater reliability.
  4. Background Work Undertaken LUMEN was co-developed with clinicians and stakeholders using a Modified Delphi process involving 150 clinicians, primarily old age psychiatrists. This produced 2,600 questions mapped to validated dementia tools, ensuring clinical relevance. Early technical testing evaluated open-source LLMs (e.g., Mistral 7B, LLaMA2 7B) using simulated clinical vignettes. ROC curve analysis demonstrated an AUC of 0.89 for distinguishing dementia-related narratives, and Cohen's Kappa 0.82 indicated high inter-rater reliability between LUMEN's outputs and clinician ratings. Early PPIE (Patient and Public Involvement and Engagement) feedback highlighted the need for simpler language, cultural sensitivity, and improved user experience. These insights will be further refined through the proposed co-production workshops.
  5. Study Design and Methodology This study will employ a mixed-methods approach, combining quantitative usability testing with qualitative interviews to evaluate LUMEN's feasibility and acceptability.

4.1. Participants and Recruitment

  • Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent.
  • Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment.
  • Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience.

4.2. Study Procedures

  1. Baseline Data Collection:
  • Demographics (age, gender, ethnicity, socioeconomic status).
  • Clinical diagnosis (where available).
  • Cognitive test scores (MoCA/ACE).
  1. LUMEN Interaction:
  • Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (~20-30 min).
  • Clinicians will review LUMEN-generated histories to assess completeness and clinical utility.
  1. Usability and Cognitive Load Assessment:
  • SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
  • NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload).
  1. Qualitative Evaluation:
  • Semi-structured interviews (n=10 carers, n=4-5 clinicians).
  • Co-production workshops with community groups to explore language, cultural representation, and accessibility.
  1. Exploratory Analysis:
  • Inter-rater reliability (Cohen's Kappa): Agreement between LUMEN outputs and clinician assessments.
  • Diagnostic accuracy (AUROC curve analysis): Comparison of LUMEN's assessments with clinical diagnoses.
  1. Milestones and Timescales

The study will run for 12 months (April 2025 - April 2026), with key phases as follows:

Phase Month Activities Preparation \& Ethics 1-3 Final IRAS approval, NHS R\&D approvals, team setup Recruitment \& Data Collection 4-9 Patient-carer dyad recruitment, clinician recruitment, LUMEN testing Usability Workshops 6-8 Co-production workshops, qualitative interviews Data Analysis \& Refinement 9-10 Thematic analysis, SUS/NASA-TLX scoring, LLM refinements Final Reporting \& Next Steps 11-12 Dissemination, grant preparation for large-scale validation study 6. Expected Impact This study will generate critical feasibility data to inform a larger clinical validation study and subsequent NHS integration. Expected outcomes include:

  • A refined, co-designed LUMEN prototype with improved usability and accessibility.
  • Quantitative evidence on usability and cognitive workload, supporting future funding applications.
  • Preliminary insights into AI-assisted collateral history-taking, laying the foundation for regulatory approval as a Software as a Medical Device (SaMD).
  • Potential for early NHS adoption under the MHRA framework, streamlining dementia diagnostics.
Conditions
Dementia
Being tested
LUMEN prototype software interaction
Keywords
Dementia, Alzheimer's Disease, Artificial Intelligence, Large Language Models
Medical subject headings
Dementia, Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LUMEN prototype software interactionOther

    This is a prototype software which seeks to gather collateral information relevant to a dementia clinical assessment.

Study groups in NCT07347431
Study groupRoleWhat they receive
Patient-carer dyadsCarers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent. • Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment. 1. Baseline Data Collection: * Demographics (age, gender, ethnicity, socioeconomic status). * Clinical diagnosis (where available). * Cognitive test scores (MoCA/ACE). 2. LUMEN Interaction: o Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (~20-30 min). 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=10 carers).
Receives: Other: LUMEN prototype software interaction
Clinicians4.1. Participants and Recruitment • Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience. 4.2. Study Procedures 1. Baseline Data Collection: o Demographics (age, gender, ethnicity, socioeconomic status). 2. LUMEN Interaction: o Clinicians will review LUMEN-generated histories to assess completeness and clinical utility. 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=4-5 clinicians).
Receives: Other: LUMEN prototype software interaction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SUS (System Usability Scale)

    10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).

    Measured: Immediately after use of software

  2. NASA-TLX (Task Load Index):

    Evaluates perceived cognitive workload (scores 0-29 = low workload).

    Measured: Immediately after prototype interaction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jan 2026
  2. Study start19 Mar 2026
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07347431
Sponsor's protocol ID
NHCT0571
Acronym
LUMEN
Status last verified
Mar 2026
First submitted
8 Jan 2026
Last updated
21 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: This will include personal narratives of participants' dementia journeys which may contain sensitive information

Questions about this trial

What is this clinical trial studying?

An observational study of Dementia, run by Northumbria Healthcare NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Judith R Harrison, MBChB (+441912081314, Judith.Harrison@newcastle.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SUS (System Usability Scale) (time frame: Immediately after use of software). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in